Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

RxSight (RXST) EBITDA Margin (2020 - 2025)

RxSight's EBITDA Margin history spans 6 years, with the latest figure at 28.09% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1244.0% year-over-year to 28.09%; the TTM value through Dec 2025 reached 29.04%, down 954.0%, while the annual FY2025 figure was 29.04%, 954.0% down from the prior year.
  • EBITDA Margin reached 28.09% in Q4 2025 per RXST's latest filing, up from 31.77% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 15.65% in Q4 2024 to a low of 275.27% in Q2 2021.
  • Average EBITDA Margin over 5 years is 93.95%, with a median of 61.25% recorded in 2023.
  • The largest YoY upside for EBITDA Margin was 20481bps in 2021 against a maximum downside of -95411bps in 2021.
  • A 5-year view of EBITDA Margin shows it stood at 186.84% in 2021, then skyrocketed by 48bps to 96.76% in 2022, then skyrocketed by 67bps to 31.92% in 2023, then skyrocketed by 51bps to 15.65% in 2024, then crashed by -80bps to 28.09% in 2025.
  • Per Business Quant, the three most recent readings for RXST's EBITDA Margin are 28.09% (Q4 2025), 31.77% (Q3 2025), and 35.43% (Q2 2025).